Olodanrigan | Interleukin Related interleukin-related.com

Product Name :
Olodanrigan

Search keywords :
Olodanrigan

drugId :
null

Target Vo:
Angiotensin II receptor type 2

Target Vo Short Name :
AT2

Moa_Name:
Angiotensin II receptor type 2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Pfizer Inc

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Neuralgia, Postherpetic

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Mirvetuximab site
Ozoralizumab Biological Activity
SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody (YA918): SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody (YA918) is an unconjugated, approximately 46 kDa, mouse-derived, anti-SARS-CoV-2 (2019-nCoV) Nucleocapsid (YA918) monoclonal antibody. SARS-CoV-2 (2019-nCoV) Nucleocapsid Antibody (YA918) can be used for: WB, ELISA expriments in background without labeling.

Author: Interleukin Related

Related Posts